Retinoic Acid Receptor β2 Agonists Restore Glycemic Control In Diabetes and Reduce Steatosis.
CONCLUSIONS: Collectively, our data show that orally active, rapidly acting, high affinity pharmacological agonists for RARβ2 improve the diabetic phenotype while reducing lipid levels in key insulin target tissues. We suggest that RARβ2 agonists should be useful drugs for T2D therapy and for treatment of hepatic steatosis.
PMID: 26462866 [PubMed - as supplied by publisher]
Source: Diabetes Metab - Category: Endocrinology Authors: Trasino SE, Tang XH, Jessurun J, Gudas LJ Tags: Diabetes Obes Metab Source Type: research
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Genetics | Insulin | Liver | Liver Disease | Mitochondrial Disease | Nutrition | Obesity | Pancreas | Urology & Nephrology | Vitamins